[Shingles vaccine: which recommendations in 2014?].
Zostavax, a live attenuated vaccine against shingles (herpes zoster) has been available in Switzerland since 2008. In a population aged 60 and over, evidence suggests the vaccine effectively reduces the incidence of shingles and some of its corresponding complications. More importantly, in terms of public health, vaccination appears to reduce the burden of illness and be pharmaco-economically viable. Despite being part of the vaccination programmes in the United States and several European countries, the vaccine is not yet part of the Swiss vaccination programme. Should Switzerland follow suit by incorporating Zostavax into their vaccination policy?
J
J
Vionnet
K
K
Hart
F
F
Spertini
D017281:Cost of Illness; D017850:Economics, Pharmaceutical; D006291:Health Policy; D006562:Herpes Zoster / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control*; D053061:Herpes Zoster Vaccine / Q000008:administration & dosage* / Q000191:economics; D006801:Humans; D017589:Immunization Programs; D015994:Incidence; D008875:Middle Aged; D011634:Public Health; D013557:Switzerland; D014611:Vaccination / Q000191:economics / Q000379:methods*; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000191:economics
D053061:Herpes Zoster Vaccine; D014613:Vaccines, Attenuated